Signalome-wide mapping of the NFκB pathway in T-cells reveals novel targets for immunotherapy

This study introduces a scalable, perturbation-based framework that maps the NFκB signaling architecture in T-cells using functional outputs rather than direct phosphorylation measurements, successfully identifying novel negative regulators like TRRAP and CTDSPL2 that enhance T-cell cytotoxicity and cytokine production when disrupted.

The Gist

Imagine your T-cells are like elite special forces soldiers. Their job is to patrol your body, find bad guys (like cancer cells), and neutralize them. To do this, they need to receive a clear "attack" signal from their commander (the antigen on the cancer cell).

For a long time, scientists tried to understand how these soldiers receive and process orders by looking at the messengers running between the command center and the troops. They looked at chemical messages (phosphorylation) trying to see who was shouting what. But in a real battlefield (a living body), these messengers are often quiet, fleeting, or hard to hear over the noise. It's like trying to understand a complex military strategy by only listening to the radio static; you might miss the actual orders.

The Big Idea: Listen to the Action, Not the Radio
Instead of trying to hear the quiet radio chatter, the researchers in this paper decided to watch the soldiers' actions. They asked: "If we break a specific part of the soldier's gear, does the attack still happen?"

They built a special "training ground" using T-cells that light up (glow green) when they successfully receive an attack order. Then, they systematically broke thousands of different parts of the T-cell's internal machinery (genes) to see which ones stopped the light from turning on.

The Experiment: The "Signalome" Scavenger Hunt
Think of the T-cell's internal wiring as a massive city with 706 different power plants, bridges, and control towers (genes). The researchers went through this city, turning off one power plant at a time, and watched to see if the city's lights (the T-cell's attack response) went out.

1. The Setup: They created a scenario where T-cells had to physically touch a cancer cell to get the "attack" signal. This is much harder than just shouting at them from a distance.
2. The Screen: They tested 706 genes. Some genes were like the main power lines (essential for the light to turn on), while others were like backup generators or traffic controllers.
3. The Discovery:
   • The "Buffer" Effect: They found something fascinating. When the enemy signal was weak (a low-affinity antigen), the T-cell relied heavily on a specific switch called LCK. If you broke LCK, the attack failed. But when the enemy signal was loud and clear (high-affinity), the T-cell didn't care as much if LCK was broken; it had other ways to get the job done. It's like driving a car: if the road is icy (weak signal), you need perfect brakes (LCK). But if the road is dry and you're speeding (strong signal), you can still stop even if the brakes are a bit sticky.
   • The Hidden Brakes: Most of the time, breaking a gene made the T-cell weaker. But they found two genes, TRRAP and CTDSPL2, that acted like hidden brakes. When they broke these genes, the T-cells didn't just work normally; they went into "overdrive." They became super-aggressive, killing cancer cells faster and releasing more weapons (cytokines).

Why This Matters
Imagine you are trying to fix a car that won't start.

• Old Way: You look at the spark plugs and wires (the molecular messengers) to see if they are firing.
• New Way (This Paper): You just try to drive the car. If you remove the handbrake and the car suddenly zooms forward, you know the handbrake was holding it back.

The researchers found two "handbrakes" (TRRAP and CTDSPL2) that T-cells use to keep themselves calm. By removing these brakes, they can make T-cells much more effective at fighting cancer.

The Takeaway
This paper gives us a new map of how T-cells think and act. Instead of just looking at the chemical signals, they looked at the final result. They discovered that:

1. T-cells have a "safety buffer" that lets them work even when the signal is weak or parts are missing.
2. There are specific "brakes" (TRRAP and CTDSPL2) that, if removed, turn T-cells into super-soldiers.

This opens the door for new cancer immunotherapies. Instead of just trying to boost the signal, doctors might be able to cut the brakes, allowing the patient's own immune system to fight cancer more effectively and aggressively.

Technical Summary

1. Problem Statement

Cellular signaling networks are fundamental to immune responses, yet their architecture remains incompletely defined. Current understanding suffers from two major limitations:

• Bias toward well-characterized components: Existing knowledge focuses heavily on a small subset of known kinases and phosphatases, leaving ~30–50% of cellular targets unexplored.
• Inadequacy of molecular readouts in physiological contexts: Traditional methods (e.g., phosphoproteomics, mass cytometry/CyTOF) rely on measuring direct molecular intermediates like phosphorylation. In physiological settings involving direct cell–cell interactions (e.g., T-cell targeting tumor cells), signaling flux is often low and spatially constrained. Consequently, these methods often fail to detect signaling events despite robust functional outcomes (e.g., cytotoxicity), leading to a disconnect between molecular measurements and biological function.

2. Methodology

The authors developed a perturbation-based experimental framework that infers signaling pathway architecture using quantitative functional outputs rather than direct molecular measurements.

• Model System Construction:

  • Generated a Jurkat T-cell reporter line expressing an NF-κB-driven GFP reporter.
  • Engineered the cells to express the 1G4 T-cell receptor (TCR) specific for the NY-ESO-1 antigen (presented by HLA-A*02:01) and deleted endogenous TCRs (TRAC/TRBC) to ensure antigen specificity.
  • Established a co-culture system with A375 melanoma cells pulsed with NY-ESO-1 peptides of varying affinities (low-affinity 6T vs. high-affinity 9V) to mimic physiological T-cell–target cell engagement.

• Signalome-Wide CRISPR-Cas9 Screen:

  • Defined a curated "signalome" library of 706 genes, including kinases, phosphatases, and adaptor/scaffolding proteins (specifically SH2-domain containing proteins).
  • Performed an arrayed CRISPR-Cas9 screen in the Jurkat reporter line. Each gene was targeted with two sgRNAs.
  • Readout: Quantified NF-κB activation via GFP expression over time using IncuCyte imaging. The primary metric was the Area Under the Curve (AUC) of GFP intensity, normalized to controls.

• Validation in Primary Human T-Cells:

  • Developed a scalable workflow for primary human CD8⁺ T-cells using lentiviral sgRNA delivery followed by Cas9 electroporation.
  • Utilized a bispecific T-cell engager (anti-CD3 fused to a gp100-targeting scFv) to activate polyclonal primary T-cells against gp100-pulsed A375 cells, bypassing the need for cognate antigen specificity while maintaining physiological signaling.
  • Validated findings in TCR-engineered primary CD8⁺ T-cells (1G4-TCR+) to confirm antigen-specific effects.
  • Assessed functional outputs: Cytotoxicity (tumor cell killing via IncuCyte), degranulation (CD107a), and cytokine production (IFNγ).

• Transcriptomic Analysis:

  • Performed RNA-seq on primary CD8⁺ T-cells following perturbation of novel targets to understand transcriptional reprogramming.

3. Key Contributions

• Functional-First Signaling Mapping: Established a scalable strategy to map signaling dependencies by quantifying downstream functional outputs (NF-κB activity, cytotoxicity) rather than relying on transient phosphorylation events that are often undetectable in cell–cell co-cultures.
• Signalome-Wide Quantitative Map: Generated a high-resolution dependency map of the NF-κB pathway in T-cells, covering 706 signaling genes.
• Discovery of Novel Regulators: Identified TRRAP and CTDSPL2 as previously unrecognized negative regulators of T-cell effector function.
• Characterization of Signal Strength Buffering: Demonstrated that proximal signaling nodes exhibit signal-strength-dependent buffering, where high-affinity antigen stimulation can compensate for the loss of certain kinases (e.g., LCK).

4. Key Results

• Screen Performance and Validation:

  • The screen showed high technical robustness (80% concordance between sgRNAs per gene).
  • It successfully recovered canonical TCR regulators (LCK, ZAP70, LCP2, ITK) as top negative regulators of NF-κB activation, validating the approach.
  • Distributed vs. Bottleneck Control: The analysis revealed distinct control patterns across protein families. SH2-domain proteins showed broad, distributed engagement (many members contribute), whereas MAPK pathway regulation was concentrated in a few "bottleneck" nodes (e.g., MAPK1/3, MAPK14).

• Context-Dependent Buffering:

  • Comparison of low-affinity (6T) vs. high-affinity (9V) stimulation revealed that LCK disruption severely impaired NF-κB activation under low-affinity conditions but had a markedly reduced effect under high-affinity stimulation. This indicates that strong signaling inputs can buffer the loss of proximal kinases.

• Primary T-Cell Validation:

  • Perturbation of SH2-domain genes in primary CD8⁺ T-cells mirrored the Jurkat screen results, confirming the conservation of signaling dependencies.
  • Disruption of known negative regulators (e.g., SLA2, PTEN) enhanced cytotoxicity, while disruption of positive regulators (LCK, LCP2) reduced it.

• Novel Negative Regulators (TRRAP and CTDSPL2):

  • TRRAP: A pseudokinase scaffold for histone acetyltransferase complexes. Its disruption in primary CD8⁺ T-cells significantly enhanced cytotoxicity, IFNγ secretion, and degranulation.
    • Mechanism: RNA-seq revealed that TRRAP loss shifts T-cells from a proliferative state (downregulation of cell cycle genes like CENPA, PLK1) to an inflammatory/effector state (upregulation of IL2, IL23R, TNFSF4).
  • CTDSPL2: A poorly characterized serine/threonine phosphatase. Its disruption also enhanced cytotoxicity and effector functions.
    • Mechanism: Unlike TRRAP, CTDSPL2 depletion caused minimal global transcriptional reprogramming, suggesting its effect is mediated through altered signaling dynamics rather than broad transcriptional changes.
  • Safety Profile: Disruption of either gene did not increase expression of exhaustion markers (PD-1, LAG-3, TIM-3), suggesting they are safe targets for enhancing immunotherapy without inducing T-cell dysfunction.

5. Significance

• Overcoming Physiological Detection Limits: The study proves that functional readouts are superior to phosphoproteomics for mapping signaling in physiologically relevant, low-flux cell–cell interactions.
• Therapeutic Targets for Immunotherapy: The identification of TRRAP and CTDSPL2 provides novel targets for enhancing T-cell-based therapies (e.g., CAR-T, TCR-T). Disrupting these genes boosts T-cell killing and cytokine production without inducing exhaustion.
• Generalizable Framework: The perturbation-based, functional-output approach offers a generalizable strategy for reconstructing signaling architecture in other complex biological systems where direct molecular measurements are insufficient.
• Refining Signaling Models: The findings challenge linear views of signaling, highlighting that control is unequally distributed (some families are distributed, others are bottlenecked) and highly dependent on signal strength (ligand affinity).